AIMS: We aimed to compare mean and between subject variability in haemoglobin (Hb) and erythropoiesis-stimulating agents (ESA) dose across the ESA compounds used to treat anaemia in dialysis patients. METHODS: We performed a meta-analysis of randomized trials evaluating ESA in adult patients with chronic kidney disease on dialysis (target Hb 9-13.5 g dl(-1)), and compared mean Hb and its standard deviation (SD), and ESA dose and its coefficient of variation (CV) between the different agents [rHuEPO alfa or beta, darbepoetin alfa, pegylated-epoetin beta (PEG-EPO) or other epoetins]. The effect of route and frequency of administration, frequency of dose adjustments, study blinding and type, baseline value, Hb target and sampling frequency were also assessed. RESULTS: Among 4983 patients from 16 studies, pooled Hb mean and SD during the evaluation phase were 11.5 g dl(-1) (95% CI 11.3, 11.7) and 0.99 g dl(-1) (0.88, 1.09), respectively. The Hb mean and SD were not significantly influenced by the covariates tested. Only Hb SD was significantly lower in maintenance studies relative to correction studies. No differences in mean ESA dose and CV were found across the covariates, except that PEG-EPO monthly dose was 42% higher than the every 2 weeks dose and the rHuEPO i.v. dose was 32% higher than the s.c. dose. CONCLUSIONS: Between subject variability in haemoglobin and ESA dose in dialysis patients is not associated with the type of ESA, nor with the dosing interval or route of administration, except for higher dose requirements in PEG-EPO monthly administration relative to every 2 weeks or rHuEPO i.v. relative to s.c.
AIMS: We aimed to compare mean and between subject variability in haemoglobin (Hb) and erythropoiesis-stimulating agents (ESA) dose across the ESA compounds used to treat anaemia in dialysis patients. METHODS: We performed a meta-analysis of randomized trials evaluating ESA in adult patients with chronic kidney disease on dialysis (target Hb 9-13.5 g dl(-1)), and compared mean Hb and its standard deviation (SD), and ESA dose and its coefficient of variation (CV) between the different agents [rHuEPO alfa or beta, darbepoetin alfa, pegylated-epoetin beta (PEG-EPO) or other epoetins]. The effect of route and frequency of administration, frequency of dose adjustments, study blinding and type, baseline value, Hb target and sampling frequency were also assessed. RESULTS: Among 4983 patients from 16 studies, pooled Hb mean and SD during the evaluation phase were 11.5 g dl(-1) (95% CI 11.3, 11.7) and 0.99 g dl(-1) (0.88, 1.09), respectively. The Hb mean and SD were not significantly influenced by the covariates tested. Only Hb SD was significantly lower in maintenance studies relative to correction studies. No differences in mean ESA dose and CV were found across the covariates, except that PEG-EPO monthly dose was 42% higher than the every 2 weeks dose and the rHuEPO i.v. dose was 32% higher than the s.c. dose. CONCLUSIONS: Between subject variability in haemoglobin and ESA dose in dialysis patients is not associated with the type of ESA, nor with the dosing interval or route of administration, except for higher dose requirements in PEG-EPO monthly administration relative to every 2 weeks or rHuEPO i.v. relative to s.c.
Authors: Steven M Brunelli; Katherine E Lynch; Elizabeth D Ankers; Marshall M Joffe; Wei Yang; Ravi I Thadhani; Harold I Feldman Journal: Clin J Am Soc Nephrol Date: 2008-10-15 Impact factor: 8.237
Authors: Bernard Canaud; Giulio Mingardi; Johann Braun; Pedro Aljama; Peter G Kerr; Francesco Locatelli; Giuseppe Villa; Bruno Van Vlem; Alan W McMahon; Cécile Kerloëguen; Ulrich Beyer Journal: Nephrol Dial Transplant Date: 2008-06-27 Impact factor: 5.992
Authors: Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo Journal: Clin Pharmacokinet Date: 2013-12 Impact factor: 6.447
Authors: Javier Arrieta; Iñigo Moina; José Molina; Isabel Gallardo; María Luisa Muñiz; Carmen Robledo; Oscar García; Fernando Vidaur; Rosa Inés Muñoz; Izaskun Iribar; Román Aguirre; Antonio Maza Journal: Int J Nephrol Renovasc Dis Date: 2014-10-09
Authors: Peter Valent; Guntram Büsche; Igor Theurl; Iris Z Uras; Ulrich Germing; Reinhard Stauder; Karl Sotlar; Wolfgang Füreder; Peter Bettelheim; Michael Pfeilstöcker; Rainer Oberbauer; Wolfgang R Sperr; Klaus Geissler; Jürg Schwaller; Richard Moriggl; Marie C Béné; Ulrich Jäger; Hans-Peter Horny; Olivier Hermine Journal: Haematologica Date: 2018-08-03 Impact factor: 9.941